Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

• Status: Recruiting
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This proposal is based on findings from our previous work involving ferumoxytol-enhanced cardiac magnetic resonance angiography. The resolution of the pulmonary vasculature based on our previous imaging protocol was exceptional (PMID: 26786296). In the Partners Healthcare System between January 1, 2014 and January 1, 2015 there were 541 patients evaluated in Partners Healthcare-affiliated hospitals with a diagnosis of pulmonary embolism and acute or chronic kidney disease at the same visit between 01/01/2014 and 01/01/2015. Ventilation perfusion scanning was performed in 201 patients during this same time interval. Up to 63% of these patients in one year did not receive the diagnostic test of choice.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Ferrosoferric Oxide

Criteria

Inclusion Criteria:

• Patients with a clinical suspicion for pulmonary embolus

• estimated glomerular filtration rate (eGFR) <30mL/min/1.73m2

• have been clinically disqualified from the use of iodine-based contrast studies, gadolinium-based contrast studies or nuclear-based detection studies

Exclusion Criteria:

• received ferumoxytol in the previous six months

• anaphylactic reaction to other intravenous iron formulations

• calculated estimated glomerular filtration rate is >50mL/min/1.78m2

• patients on dialysis with no residual renal function

• pregnant women and nursing mothers. Standard screening will be used by

• patients >65 years of age with BMI >45, and/or liver disease (Child-Pugh class C)